Bokf Na Sells 18,412 Shares of Pfizer Inc. (NYSE:PFE)

Bokf Na cut its stake in Pfizer Inc. (NYSE:PFE) by 12.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 124,661 shares of the biopharmaceutical company’s stock after selling 18,412 shares during the period. Bokf Na’s holdings in Pfizer were worth $3,331,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in PFE. Range Financial Group LLC acquired a new position in shares of Pfizer in the 4th quarter valued at about $353,000. Sterneck Capital Management LLC lifted its stake in Pfizer by 76.2% in the fourth quarter. Sterneck Capital Management LLC now owns 32,630 shares of the biopharmaceutical company’s stock valued at $866,000 after buying an additional 14,107 shares during the period. InvesTrust bought a new position in shares of Pfizer during the 4th quarter worth approximately $5,246,000. Legacy Private Trust Co. increased its stake in shares of Pfizer by 29.0% in the 4th quarter. Legacy Private Trust Co. now owns 13,766 shares of the biopharmaceutical company’s stock valued at $365,000 after acquiring an additional 3,093 shares in the last quarter. Finally, First International Bank & Trust acquired a new position in shares of Pfizer during the 4th quarter valued at $240,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on PFE. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Cantor Fitzgerald assumed coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective for the company. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Price Performance

Shares of NYSE:PFE opened at $22.78 on Thursday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $129.18 billion, a PE ratio of 16.15, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The stock’s fifty day simple moving average is $24.15 and its two-hundred day simple moving average is $25.65.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.82 earnings per share. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.55%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s payout ratio is 124.64%.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.